GlaxoSmithKline to supply U.S. with $196M worth of anthrax fighter

GlaxoSmithKline ($GSK) inked a $196 million contract to supply its anthrax remedy, raxibacumab, to the U.S. government for stockpiling in case of a bio-terrorist attack. Release | Report